The amino acid response to a mixed meal in patients with type 2 diabetes: Effect of sitagliptin treatment

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1140-1147

  Muscelli, E ^a   Frascerra, S ^a   Casolaro, A ^a   Baldi, S ^a   Mari, A ^b   Gall, W ^c   Cobb, J ^c   Ferrannini, E ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

^c METABOLON INC   (United States)

Author keywords

T2D; 1 linoleoyl glycerophosphocholine; Branched chain aminoacids; Sitagliptin; hydroxybutyrate

Indexed keywords

ALPHA HYDROXYBUTYRATE; AMINO ACID; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HYDROXYBUTYRIC ACID; PLACEBO; SITAGLIPTIN; UNCLASSIFIED DRUG; 2-HYDROXYBUTYRIC ACID; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; INSULIN; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; AMINO ACID METABOLISM; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DRUG EFFECT; FAT FREE MASS; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; MEAL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; FEMALE; HUMANS; HYDROXYBUTYRATES; INSULIN; INSULIN RESISTANCE; MALE; MEALS; MIDDLE AGED; PYRAZINES; TRIAZOLES;

EID: 84914155689     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12350     Document Type: Article

References (36)

1. Luck JM, Morse SW. The effects of insulin and adrenaline on the amino-acid content of the blood. Biochem J 1933; 27: 1648-1654.
2. Luetscher JA. The metabolism of amino acids in diabetes mellitus. J Clin Invest 1942; 21: 275-279.
3. Felig P, Marliss E, Cahill GF Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med 1969; 281: 811-816.
4. Newgard CB, An J, Bain JR et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9: 311-326.
5. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012; 15: 606-614.
6. Pietiläinen KH, Naukkarinen J, Rissanen A et al. Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity. PLoS Med 2008; 5: e51.
7. Wang TJ, Larson MG, Vasan RS et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17: 448-453.
8. Würtz P, Soininen P, Kangas AJ et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care 2013; 36: 648-655.
9. Floegel A, Stefan N, Yu Z et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013; 62: 639-648.
10. Shaham O, Wei R, Wang TJ et al. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 2008; 4: 214.
11. Ho JE, Larson MG, Vasan RS et al. Metabolite profiles during oral glucose challenge. Diabetes 2013; 62: 2689-2698.
12. Marchesini G, Bianchi G, Rossi B, Muggeo M, Bonora E. Effects of hyperglycaemia and hyperinsulinaemia on plasma amino acid levels in obese subjects with normal glucose tolerance. Int J Obes Relat Metab Disord 2000; 24: 552-558.
13. Pijl H, Potter van Loon BJ et al. Insulin-induced decline of plasma amino acid concentrations in obese subjects with and without non-insulin-dependent diabetes. Metabolism 1994; 43: 640-646.
14. Floyd JC, Fajans SS, Conn JW, Knopf RF, Rull J. Stimulation of insulin secretion by amino acids. J Clin Invest 1966; 45: 1487-1502.
15. Floyd JC Jr, Fajans SS, Conn JW, Thiffault C, Knopf RF, Guntsche E. Secretion of insulin induced by amino acids and glucose in diabetes mellitus. J Clin Endocrinol Metab 1968; 28: 266-276.
16. Krause MS, McClenaghan NH, Flatt PR, de Bittencourt PI, Murphy C, Newsholme P. L-arginine is essential for pancreatic β-cell functional integrity, metabolism and defense from inflammatory challenge. J Endocrinol 2011; 211: 87-97.
17. Manders RJ, Wagenmakers AJ, Koopman R et al. Co-ingestion of a protein hydrolysate and amino acid mixture with carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am J Clin Nutr 2005; 82: 76-83.
18. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994; 107: 1848-1855.
19. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
20. Muscelli E, Mari A, Casolaro A et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-1348.
21. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10-18.
22. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
23. Muscelli E, Casolaro A, Gastaldelli A et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 2818-2826.
24. Gall WE, Beebe K, Lawton KA et al., RISC Study Group. Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One 2010; 5: e10883.
25. Ferrannini E, Natali A, Camastra S et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 2013; 62: 1730-1737.
26. Buzzigoli G, Lanzone L, Ciociaro D et al. Characterization of a reversed-phase high-performance liquid chromatographic system for the determination of blood amino acids. J Chromatogr 1990; 507: 85-93.
27. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of β-cell action: modelling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002; 283: E1159-E1166.
28. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24: 539-548.
29. Adeva MM, Calviño J, Souto G, Donapetry C. Insulin resistance and the metabolism of branched-chain amino acids in humans. Amino Acids 2012; 43: 171-181.
30. Tessari P, Nosadini R, Trevisan R et al. Defective suppression by insulin of leucine-carbon appearance and oxidation in type 1, insulin-dependent diabetes mellitus. Evidence for insulin resistance involving glucose and amino acid metabolism. J Clin Invest 1986; 77: 1797-1804.
31. Lillioja S, Mott DM, Spraul M et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988-1992.
32. Kadota Y, Toyoda T, Kitaura Y, Adams SH, Shimomura Y. Regulation of branched-chain α-ketoacid dehydrogenase complex in rats fed a high-fat diet. Obes Res Clin Pract 2013; 7: e439-e444.
33. Sears DD, Hsiao G, Hsiao A et al. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci U S A 2009; 106: 18745-18750.
34. Shah SH, Crosslin DR, Haynes CS et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. Diabetologia 2012; 55: 321-330.
35. Newsholme P, Krause M. Nutritional regulation of insulin secretion: implications for diabetes. Clin Biochem Rev 2012; 33: 35-47.
36. Gannon MC, Nuttall FQ. Amino acid ingestion and glucose metabolism-a review. IUBMB Life 2010; 62: 660-668.